Current status of best-studied risk stratification schemes for major bleeding in patients with VTE
| . | ACCP risk table3 . | VTE-BLEED19 . | RIETE33 . | HAS-BLED38 . |
|---|---|---|---|---|
| External evaluation in retrospective study | ✓ | ✓ | ✓ | ✓ |
| External evaluation in prospective study | ✓ | ✓ | ✓ | ✓ |
| Evaluated in patients treated with VKA | ✓ | ✓ | ✓ | ✓ |
| Evaluated in patients treated with DOACs | ✓ | ✓ | ✓ | ✓ |
| Evaluated in patients treated with direct Xa inhibitors | ✓ | ✓ | ✓ | ✓ |
| Evaluated in patients treated with direct thrombin inhibitors | ✓ | |||
| Association with risk of recurrent VTE established | ✓ | |||
| Association with risk of fatal/intracranial bleeding established | ✓ | |||
| Performance during long-term treatment established | ✓ | ✓ | ✓ | |
| Performance in patients with unprovoked VTE established | ✓ | |||
| Prospective validation in outcome study |
| . | ACCP risk table3 . | VTE-BLEED19 . | RIETE33 . | HAS-BLED38 . |
|---|---|---|---|---|
| External evaluation in retrospective study | ✓ | ✓ | ✓ | ✓ |
| External evaluation in prospective study | ✓ | ✓ | ✓ | ✓ |
| Evaluated in patients treated with VKA | ✓ | ✓ | ✓ | ✓ |
| Evaluated in patients treated with DOACs | ✓ | ✓ | ✓ | ✓ |
| Evaluated in patients treated with direct Xa inhibitors | ✓ | ✓ | ✓ | ✓ |
| Evaluated in patients treated with direct thrombin inhibitors | ✓ | |||
| Association with risk of recurrent VTE established | ✓ | |||
| Association with risk of fatal/intracranial bleeding established | ✓ | |||
| Performance during long-term treatment established | ✓ | ✓ | ✓ | |
| Performance in patients with unprovoked VTE established | ✓ | |||
| Prospective validation in outcome study |